ASTRAZENECA and Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) officially initiated the launch of the Contract Manufacturing Operation arrangement (CMO) in the Kingdom of Saudi Arabia (KSA). Representatives from both companies signed the agreement to conclude an Investment, Development and Technology Transfer initiative.
The signing ceremony took place in Gothenburg, Sweden, in the presence of Dr. Tawfiq Al Rabiah, minister of health, following the memorandum of understanding that was signed between AstraZeneca and SPIMACO earlier in March during the official visit of the Crown Prince Muhammed bin Salman to the United Kingdom.
SPIMACO’s Chief Executive Officer, Fahad Al Khalaf said, “Our agreement with AstraZeneca will focus on technology transfer of five medical products (11 SKUs) that are valued at around SR300 million per annum, where three of these products will require a special and separate unit for manufacturing purposes.”
“This strategic alliance is of paramount importance, and one which reflects the company’s keen interest to provide the latest treatment and therapies for patients and care providers in the Kingdom that are aligned to the highest global standards, reflecting the company’s leading position as one of the largest drug production companies. SPIMACO aims to secure supply through local manufacturing,” added Al Khalaf.
The $80 million deal aims to extend access to around 3 million patients across Saudi Arabia, with locally produced innovative medicines that are highly relevant to local medical needs in the cardiovascular, diabetes and gastrointestinal areas. Alongside the innovation being localized, this CMO will play a key role in developing highly skilled local Saudi talent.
According to the World Health Organization (WHO), non-communicable diseases (NCDs) account for 71% of all deaths in Saudi Arabia, with cardiovascular disease being the leading cause of mortality.
As part of the Vision 2030, Saudi Arabia’s National Transformation Program (NTP) focuses on key elements across the healthcare industry that include increased use of technology, healthcare education, enhanced professional development as well as local manufacturing of pharmaceuticals.
Ismail Shehada, country president Saudi Arabia – AstraZeneca also noted, “Saudi Arabia is at the heart of our regional operations in the region and AstraZeneca is committed to expand its activities in the Kingdom to meet local healthcare demands. With the current infrastructure changes to the local economy, the potential for the Saudi market is gaining more momentum to create more synergies locally and around the region, as we continue to support Vision 2030’s health agenda.”
“Our collaboration with SPIMACO is a core component of our strategic approach which focuses on further developing the pharmaceutical sector in the Kingdom with the objective of supporting a comprehensive healthcare delivery amongst consumers, patients and the local medical community,” noted Shehada.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas — Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
SPIMACO is a Saudi Joint–Stock company with a fully paid-up capital of SR1,200,000,000. It was established in 1986. SPIMACO Addwaeih’s core business is medical and pharmaceutical, which includes development, manufacturing and sales of pharmaceutical products and medical appliances. Moreover, SPIMACO also has ownership in number of joint stock and limited liabilities companies inside and outside the Kingdom. SPIMACO has developed a strong position in Saudi Arabia and is well positioned to sustain its growth and have a sound platform to serve export markets. — SG
